With the NHS opening two high energy proton beam centers next year, optimism is high in the medical community for the benefits that this could bring to many cancer patients over the coming years. However, as explained here by Adrian Crellin, MB, BChir, MA, FRCP, FRCR, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, there is still a high degree of uncertainty regarding the dosage and biological quirks of the treatment, especially when integrated with other drugs, and so the proper evaluation of proton beam therapy under academic contexts is essential for the safety of patients. This video was recorded…
Author: Editor
Even though the UKs first high energy proton beam centers are yet to open, it is critical to look forward and see where the field should be moving in the coming years. In this insightful interview, recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK, Adrian Crellin, MB, BChir, MA, FRCP, FRCR, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, gives a forecast of how the field may advance in the short term, with improvements to the technology and a better understanding of where the treatment should be indicated. Dr Crellin also speculates on the…
The NHS is opening its first two high energy proton beam therapy centers in 2018 and 2020, at great financial cost, after many years of lobbying from the medical community. However, speaking from the 2017 National Cancer Research Institue (NCRI) Conference in Liverpool, UK, Adrian Crellin, MB, BChir, MA, FRCP, FRCR, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, hypothesizes that these years convincing the government to invest may have allowed the UKs entry into the proton beam therapy field to come at the perfect time. Dr Crellin highlights great recent advancements in the technology used in the treatment, which…
The dissemination and sharing of scientific knowledge is key to improving healthcare practices on a national and international scale. In this interview, filmed at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Islam Elkonaissi of The Royal Marsden NHS Foundation Trust, London, UK emphasizes the importance and utility of meetings such as BOPA, highlighting a change that his center made based on information learned at the event.
Novel immunotherapies have great potential to improve the survival of cancer patients; however, new treatments must be introduced in a regulated manner in order to plan for anticipated, and unanticipated, side effects. Here, Islam Elkonaissi of The Royal Marsden NHS Foundation Trust, London, UK describes the crucial role pharmacists will serve in the introduction of immunotherapies for cancer. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
The early diagnosis of cancer is key to survival; however, with the many demands upon the NHS this can be challenging. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Graeme Betts from the Regional Manager Health Professional Engagement Programme, Cancer Research UK, UK discusses the current landscape of cancer diagnosis and survival in the UK. Topical points covered include the survival rates of cancer patients in the UK vs. other developed nations, and the aims of CRUK in terms of cancer diagnosis and survival rates.
CRUK is well known for scientific research; however, it also employs other channels to transition the results of this research into the clinic. In this interview, Graeme Betts from the Regional Manager Health Professional Engagement Programme, Cancer Research UK, UK discusses the Facilitator programme run by CRUK, in which facilitators collaborate with healthcare professionals to optimize cancer care and outcomes. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
The CRUK Facilitator programme is collaborating with community pharmacists to provide training and resources. In this interview, Gillian Phillips from Cancer Research UK, Glasgow, UK discusses the case of the collaboration between CRUK and NHS Lanarkshire pharmacists, with the aim of spreading knowledge of cancer screening programmes. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
The earlier cancer is diagnosed, the higher the chance of recovery. At the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Gillian Phillips from Cancer Research UK, Glasgow, UK discusses how to improve cancer patient outcomes. Ms Phillips also provides an overview of the Facilitator programme run by CRUK, which works with a range of healthcare professionals, including pharmacists, to ensure early cancer diagnosis and cancer prevention.
Immunotherapy for acute myeloid leukemia (AML) is an exciting area, with clinical trials, including those that are first-in-human, showing promising results. Here, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on a range of these trials, including response rates and toxicities. Dr Konopleva covers the trial of the bispecific CD3xCD123 DART, flotetuzumab (NCT02152956); a next-generation CD123-targeting CAR T-cell therapy (NCT02159495); and the antibody-drug conjugate IMG9N77, which targets CD33 (NCT02674763). This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
There were impressive updates on venetoclax combination studies for elderly acute myeloid leukemia (AML) that are progressing at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the studies, including the combination of venetoclax with azacitidine/decitabine (NCT02203773), low-dose cytarabine (NCT02287233), and cobimetinib and idasanutlin (NCT02670044). Dr Konopleva explains the exciting data so far, highlighting the utility of these new treatments, which are much needed for elderly AML, where treatment options are very limited.
E-selectin is involved in the progression of acute myeloid leukemia (AML), playing a key role in angiogenesis, thus making it a therapeutic target. In this interview, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the clinical trial of the E-selectin inhibitor GMI-1271 in combination with high-dose cytarabine for relapsed/refractory and newly diagnosed elderly AML (NCT02306291). Excitingly, this drug has now been granted FDA breakthrough therapy designation. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
In this exciting interview from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the GEM-CESAR study (NCT02415413). This trial investigates a curative strategy for high-risk smoldering multiple myeloma (SMM), consisting of induction with carfilzomib, lenalidomide and dexamethasone (KRd), followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Dr Mateos discusses the logic behind this strategy, the results of the study in terms of progression to MM, response rates, MRD, overall survival and the safety profile of the regimen.
SYK, which directly binds to and activates FLT3, has been implicated in the pathogenesis of B-cell malignancies, making it a promising therapeutic target. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Pratz discusses the study he presented (NCT02323113), which investigated TAK-659, an oral dual SYK/FLT3 inhibitor, for relapsed or refractory acute myeloid leukemia (AML). Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, covers the promising suppression and clinical responses achieved so far, in FLT3-mutated and FLT3-unmutated patients.
There have been great advances in the targeting of FLT3 for acute myeloid leukemia (AML) in recent years, many of which were discussed at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Here, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the promising results of a Phase I study of the oral FLT3/AXL inhibitor gilteritinib (ASP2215) in combination with standard induction and consolidation chemotherapy in patients with newly diagnosed AML, which he presented at the meeting. Dr Pratz covers response and remission rates, tolerability, and the next steps for the study.
FLT3 ITD acute myeloid leukemia (AML) is associated with high rates of relapse, after which prognosis is very poor. Thus, the improvement of initial therapy for this group of patients is crucial. In this interview, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the results of a study investigating the outcomes of patients with FLT3 ITD AML, in order to identify which treatment strategies lead to the most favorable outcomes. Factors considered included the role of chemotherapy (cytarabine), targeted agents (TKIs) and MRD status pre- and post-transplant. This video was recorded at the American Society of Hematology (ASH)…
There are now several novel drugs targeting the protein kinase FLT3 in patients with acute myeloid leukemia (AML). Here, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the clinical implications of these new agents and why they may provide an advantage over current treatments. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Recent data have suggested that chronic lymphocytic leukemia (CLL) patients, in particular those with mutated immunoglobulin heavy chain genes, can have prolonged responses to FCR chemoimmunotherapy. In this interview, Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, dicusses the ecouraging results of a Phase II clinical trial (NCT02251548) investigating whether adding ibrutinib to the classic fludarabine, cyclophosphamide and rituximab (FCR) regimen would significantly improve the complete remission and minimal residual disease (MRD) negativity status of patients with CLL. Dr Brown also details the expansion of this trial folllowing its promising results. This video was recorded at the…
Ibrutinib is associated with a range of side effects, including increased bruising, TKI ecchymosis, low-grade bleeding and hemorrhage. This has led to further studies attempting to clarify the risks of ibrutinib. Here, Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, provides us with an overview of the results of an analysis of the incidence and risk factors for adverse events in patients treated with ibrutinib. The four randomized trials analyzed included three chronic lymphocytic leukemia (CLL) trials and a mantle cell lymphoma (MCL) trial. This video was recorded at the American Society of Hematology (ASH) 2017 Annual…
A range of chronic lymphocytic leukemia (CLL) research was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Dr Barrientos gives us an overview of the CLL updates, focusing on the different classes of therapy available and our growing knowledge of how they affect patient outcomes. Jacqueline Barrientos, MD, of the Feinstein Institute for Medical Research, Manhasset, NY, covers the use of tyrosine kinase inhibitors (TKIs) or venetoclax as a salvage treatment, TKI intolerance and the experimental oral PI3K delta inhibitor, umbralisib.
Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many groups are testing ibrutinib combination regimens. Here, Jacqueline Barrientos, MD, of the Feinstein Institute for Medical Research, Manhasset, NY, discusses the results of ibrutinib combinations for CLL that were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Dr Barrientos highlights the combination of ibrutinib with obinutuzumab and venetoclax. She also explains how she thinks ibrutinib combination therapy for CLL will be utilized in the future and why good ibrutinib combinations are so…
The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial (NCT01722487); however, within CLL, it has not been tested in combination or in younger patients. Here, Jacqueline Barrientos, MD, of the Feinstein Institute for Medical Research, Manhasset, NY, discusses the Phase III E1912 trial (NCT02048813), which is investigating the combination of ibrutinib and rituximab vs. classic fludarabine, cyclophosphamide and rituximab (FCR) for CLL. Dr Barrientos provides an update on the highly-anticipated trial and highlights how the results will aid in the determination of whether newer, targeted agents are better…
Decitabine, a DNA methyltransferase (DNMT) inhibitor, which is given to patients with myelodysplastic syndromes (MDS), is classically administered intravenously. Now, ASTX727, an oral combination of decitabine and the cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), is in Phase II clinical trials for the treatment of MDS (NCT02103478). Here, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the study so far compared with traditional decitabine treatment, and highlights the benefits of an oral version of this treatment. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and…
Clinical access to new technologies, such as next-generation sequencing (NGS), can revolutionize the treatment of cancer. In this interview, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, eloquently highlights the potential of NGS for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Garcia-Manero emphasizes the power of this tool for predictive screening, among a range of other utilities. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Pracinostat is a histone deacetylase (HDAC) inhibitor that has demonstrated very promising efficacy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the follow-up analysis of the Phase II trial of the drug in combination with azacitidine in elderly patients with AML. Dr Garcia-Manero also discusses the Phase III trial of pracinostat for AML, which is currently recruiting. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
In cutaneous T-cell lymphoma (CTCL) miR-155 has been shown to be upregulated. Here, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses an antogomir being developed to target this variance. MRG-106, an inhibitor of miR-155, is in Phase I trials (NCT02580552) in patients with CTCL, in addition to other lymphoid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Querfeld discusses the initial results and progression of this study.
Immune checkpoint inhibitors have now entered the treatment landscape for cutaneous T-cell lymphoma (CTCL). In this interview, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses a Phase I/II clinical trial of a PD-L1 inhibitor for CTCL. Dr Querfeld covers the response rates and what these indicate for the treatment of CTCL with immune checkpoint inhibitors. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
CAR T-cell therapies have exhibited strong and durable responses in several hematological malignancies thus far. Now bb2121, an anti-BCMA CAR T-cell product, is demonstrating impressive responses in relapsed/refractory multiple myeloma (MM). In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses the latest results of the ongoing CRB-401 trial (NCT02658929) of bb2121 for MM. Dr Lin covers the promising progress, response rates, response durability, MRD status and safety data from the trial so far. She also highlights the long-term follow-up and FDA breakthrough treatment designation of the product. This video was recorded at the American Society…
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses data being presented at the meeting for an additional cohort of the ZUMA-1 study (NCT02348216), investigating the use of tocilizumab for prophylaxis of the primary side effects of axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Lin highlights the results of this treatment in regards to reducing the severity and/or incidence of cytokine release syndrome and neurotoxicity. This video was…
Immunotherapy for lymphoid malignancies progressed dramatically in 2017, with FDA approval of two CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel. In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses future clinical trials that are planned for CAR T-cells. Dr Lin highlights the potential of innovative strategies, including utilizing novel technologies, to produce the next generation of CAR T-cells. She also emphasizes the need for and promise of managing CAR T-cell therapy-related toxicities.
The Phase I/II trial ZUMA-1 (NCT02348216) was pivotal for CAR T-cell development. In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, highlights how this led to FDA approval of the anti-CD19 second-generation CAR T-cell product, axicabtagene ciloleucel (axi-cel; KTE-C19), for refractory B-cell non-Hodgkin lymphoma (NHL). Dr Lin then discusses the exciting long-term follow-up data of this study. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
The ground-breaking PRECISION-Panc project aims to speed up scientific discovery to improve the survival rates of patients with pancreatic cancer. In this interview at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK provides an overview of the project, including its aims, work and exciting recent publications on the discovery of pancreatic adenocarcinoma subtypes. He highlights how this project has the potential to improve the time scale of testing, thus providing clinically applicable results, such as those from whole genome…
The imminent pancreatic cancer trial PRIMUS001 (ISRCTN75002153) has the potential to personalize therapy for patients with pancreatic cancer. In this interview Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK provides an overview of the design and aims of the trial, in addition to the mutated pathway in the patients recruited.
This is an exciting time for pancreatic cancer research, with advances in immunotherapy, genomic sequencing and druggable targets. What the next 10 years may look like for pancreatic cancer research is discussed by Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. In particular, he discusses the need for improving and speeding up clinical trials for this patient group moving forwards.
There is a necessity for further clinical trials and research into pancreatic cancer in order to improve patient outcomes. In this video Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK provides an overview of the typical prospects of patients with pancreatic cancer in terms of treatment options and survival, as well as managing expectations. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
Although progress has been made in the treatment of pancreatic cancer, further research is required to identify novel therapeutic options to improve the outlook of patients with this cancer. In addition, quality of life must be considered when selecting the optimal treatment. In this interview Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK discusses the current treatment landscape for pancreatic cancer and progression that has been made in this area, including the transition from single agent to triplet chemotherapy, and the advent of second line therapy trials. He also discusses quality vs.…
How can patients navigate between treatment options with all of the recent breakthroughs in myeloma therapy? Dr. Guilherme Perini, a Brazilian hematologist, joined Patient Power at the 2017 American Society of Hematology (ASH) meeting to inform myeloma patients what testing should be done and what to discuss with their doctor in order to receive the most suitable treatment for their condition. Tune in to find out the latest from this myeloma expert.
Where is lymphoma treatment today? Stay in the know with Brazilian hematologist Dr. Guilherme Perini as he discusses advances in treatment from the 2017 American Society of Hematology meeting. He also shares the challenges lymphoma patients in Brazil face in gaining access to new lymphoma therapies. Watch now to learn the latest from this lymphoma expert.
The landscape of myeloma care is constantly evolving with the development of new research and treatment. While advances in myeloma therapies are exciting and beneficial, some patients feel overwhelmed making treatment decisions between all the available options. Myeloma patient Jack Aiello leads a discussion with Dr. Robert Orlowski of The University of Texas MD Anderson Cancer Center and Dr. Noopur Raje of Massachusetts General Hospital Cancer Center as they help decipher which type of therapy is appropriate for different conditions. They also consider the role of a transplant amidst new medicines, and the impact they have on attaining minimal residual…
What have researchers discovered about ROR1 and its role in targeted CLL therapies? Andrew Schorr hosts coverage from the 2017 American Society of Hematology (ASH) conference to learn about the latest innovations in CLL research and treatment. Tune in to hear Dr. Michael Choi, from the UCSD Moores Cancer Center, discuss ROR1 and its innovative role in targeted therapies for CLL. He also shares new approved treatments and opportunities for patients to get involved with clinical trials currently being conducted.
Can todays medicines be used together to treat CLL more effectively? CLL expert Dr. Michael Choi of UC San Diego Moores Cancer Center joins Patient Powers Andrew Schorr at the 2017 American Society of Hematology (ASH) conference. Dr. Choi provides an update on current medicines and discusses promising combination therapies for CLL, including research into combining ibrutinib (Imbruvica) and venetoclax (Venclexta).
Where do things stand now with personalizing myeloma therapy to a patients genetic profile? At the American Society of Hematology (ASH) 2017 conference in Atlanta, Esther Schorr speaks with Dr. Gareth Morgan, Director of the UAMS Myeloma Institute, about new oncogenes in myeloma. They also discuss the importance of testing at the time of myeloma diagnosis to set a treatment plan. Watch for this top myeloma experts take on the latest myeloma research.
The first relatively long-term CAR T-cell trial follow-up data came out at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the ZUMA-1 (NCT02348216) study of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Siddiqi discusses the long-term data thus far on remission, response durability and toxicity.
The right balance of T-cell expansion needs to be achieved in order to obtain the optimal response to CAR T-cell therapy. To enable this, an increased understanding of the factors that affect the response is required. Here, Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses her presentation on what pre-infusion patient characteristics and biomarkers were found to affect response in the TRANSCEND-NHL-001 trial (NCT02631044) of the anti-CD19 CAR T-cell product JCAR017 for aggressive B-cell non-Hodgkin lymphoma (NHL). This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in…
Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of CRS, such as disseminated intravascular coagulation (DIC) and macrophage activation syndrome (MAS). In this interview, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses what her group observed in patients with acute lymphoblastic leukemia (ALL) following anti-CD22 CAR T-cell infusion. Dr Shah highlights the fact that we are only just starting to understand the interplay between these factors. In addition, she discusses the need to identify additional therapies to treat these side effects. This…
With CAR T-cell therapy, similarly to traditional chemotherapy, the use of a single agent will not remain effective in treating a cancer, and thus multi-agent regimens are needed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses an exciting upcoming clinical trial, which plans to combine anti-CD22 and anti-CD19 CAR T-cell therapies for patients with B-cell malignancies.
CAR T-cell therapy development is progressing across a wide range of hematological malignancies, with the results highly anticipated in acute lymphoblastic leukemia (ALL) following the exciting results seen in lymphoma. In this interview, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, provides us with an update from the ALL group of on the ongoing Phase I clinical trial of anti-CD22 CAR T-cells for B-cell malignancies (NCT02315612). This agent is particularly exciting, as it is the first CAR T-cell product that is active in ALL which does not target CD19. Dr Shah touches upon whether…
An exciting new CAR T-cell product, which targets SLAMF7 (CS1, CD319), is displaying exciting preliminary results against multiple myeloma (MM) cells. In this interview, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses its underlying design and mechanism of action, as well as the results of tests performed so far in vitro, in vivo and on patient-derived MM cells. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
A major concern surrounding novel therapeutics is their safety, which must be characterized thoroughly. Here, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety data regarding the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) from the long-term follow-up of the ZUMA-1 trial (NCT02348216). Dr Neelapu covers what the most common adverse events were, when they occurred and their reversibility. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
The latest CAR T-cell data was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes the data he presented on the long-term follow-up of the ZUMA-1 study (NCT02348216) of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma (NHL).